Please use this identifier to cite or link to this item:
Title: Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): A population based outcome study
Authors: Soon, Y.Y. 
Zheng, H.
Ho, S.Z.
Koh, W.Y. 
Leong, C.N. 
Tey, J.C.S. 
Vellayappan, B. 
Yap, S.P.
Tham, I.W.K. 
Fong, K.W. 
Keywords: aged
cancer center
cancer diagnosis
cancer radiotherapy
cancer staging
cancer survival
clinical evaluation
clinical practice
cohort analysis
disease association
disease registry
electronic medical record
health care utilization
major clinical study
nuclear magnetic resonance imaging
outcome assessment
overall survival
randomized controlled trial (topic)
retrospective study
skull irradiation
small cell lung cancer
therapy effect
treatment response
cancer staging
follow up
lung tumor
skull irradiation
small cell lung cancer
survival rate
Cranial Irradiation
Follow-Up Studies
Lung Neoplasms
Neoplasm Staging
Outcome Assessment (Health Care)
Research Design
Retrospective Studies
Small Cell Lung Carcinoma
Survival Rate
Issue Date: 2018
Publisher: BioMed Central Ltd.
Citation: Soon, Y.Y., Zheng, H., Ho, S.Z., Koh, W.Y., Leong, C.N., Tey, J.C.S., Vellayappan, B., Yap, S.P., Tham, I.W.K., Fong, K.W. (2018). Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): A population based outcome study. Radiation Oncology 13 (1) : 247. ScholarBank@NUS Repository.
Abstract: Background: The survival benefit of PCI in ES-SCLC reported by a European randomized trial (RCT) in 2007 was not replicated by a Japanese RCT published in 2017. This study aimed to evaluate the uptake of PCI before and after publication of the European RCT and its association with survival in ES-SCLC. Methods: We identified eligible patients in the only two Singapore national cancer centres from 2003 to 2010. We linked their electronic medical records to the national death registry. We described the utilization of PCI in patients diagnosed from 2003 to 2006 (pre-adoption cohort) with patients diagnosed from 2007 to 2010 (post-adoption cohort). We performed univariable and multivariable Cox regression analysis to assess the association between PCI and survival. Results: We identified 224 patients with ES-SCLC with no brain metastases. Among the 71 patients who had at least stable disease after first line chemotherapy, there was an increase in the use of PCI from the period 2007 to 2010 compared with 2003 to 2006 (32% versus 10%, P = 0.044). PCI was associated with improved OS (hazard ratio 0.22, 95% CI 0.10 to 0.47, P < 0.001) compared to no PCI in the multivariable analysis. Conclusion: There was an increase in the adoption of PCI for ES-SCLC since 2007. PCI was associated with improved survival in patients who did not have mandatory MRI brain imaging prior to PCI and had stable disease or better after first line chemotherapy, suggesting that the results of the European RCT are reproducible in the real-world practice. © 2018 The Author(s).
Source Title: Radiation Oncology
ISSN: 1748717X
DOI: 10.1186/s13014-018-1184-x
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13014-018-1184-x.pdf452.53 kBAdobe PDF



Page view(s)

checked on Jan 15, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.